Author

Rebecca C. Larson

Broad InstituteORCID 0000-0003-0174-061XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Marcela Valderrama MausiD· 2 shared Adila IzgutdinaiD· 1 shared Akul Naik· 1 shared Alexander ArmstrongiD· 1 shared Alexánder RojasiD· 1 shared Amanda A. BouffardiD· 1 shared Amit VermaiD· 1 shared Amrik S. KangiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Marcela Valderrama MausORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyJournal for ImmunoTherapy of CancerPeer-reviewedDec 1, 2025

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple…·Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologyNaturePeer-reviewedSep 24, 2025

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma

Nelson H. Knudsen, Giulia Escobar, Felix Korell…·Marcela Valderrama Maus

The paper uses in vivo CRISPR screens to identify genes affecting CAR T cell persistence and function in multiple myeloma, finding CDKN1B as a key regulator of late-stage CAR T cell fitness.

50 citationstop 1%

humangenetic perturbation / CRISPR

𝕏 PostBluesky